Bone Marrow Transplant and Stem Cell Transplant Program
The Penn Difference
Innovative Research... Advanced Medicine... Service Excellence
- Nationally recognized experts with extensive experience in bone marrow and stem cell transplant
- Advanced diagnostic testing, treatments and technologies
- Coordinated care throughout the experience
- Support services and education programs
- A reputation for sensitivity and responsiveness
- Personalized attention
- Innovative clinical trials
- The backing of a major research program with immediate translation to patient care
What sets Penn’s Bone Marrow and Stem Cell Transplant Program apart?
Penn’s program is one of the oldest and largest in the country. By putting our experience to work, we offer the best possible treatment outcomes.
Our multidisciplinary bone marrow and stem cell transplant team has dedicated their clinical and research careers to improving the field of bone marrow and stem cell transplant.
It is this relentless pursuit for the very best clinical outcome and quality of life that drives Penn’s Bone Marrow and Stem Cell Transplant Program.
Penn’s program is distinguished in a number of ways:
- Penn has one of the few Bone Marrow and Stem Cell Biology Research Programs in the country that is approved and funded by the National Cancer Institute.
- Penn has one of the largest and most experienced teams of transplant oncologists who have been working together for years.
- Penn has a dedicated hospital unit that is not only well equipped to support transplant patients, but also experienced nurses who understand the personal issues faced during transplant.
- Started in 1987, the autologous (an individual's own marrow saved before treatment) transplant program has been under the direction of Edward Stadtmauer, MD since 1992.
- We have performed over 2100 autologous transplants since the programs inception.
- Penn’s allogenic transplant program (marrow donated by someone else), has performed over 500 allogeneic transplants since its inception in including myeloablative and non-myeloablative transplants utilizing both related and unrelated donors.
- Penn pioneered the clinical trial using autologous transplant for acute myeloid leukemia (AML). This led to national trials which resulted in the use of autologous transplant as the standard of care for AML .
- Our high priority national clinical trial, for high risk and metastatic breast cancer, showed that autologous transplant versus conventional therapy did not increase survival. This trial has held up as a model for other comparison trials and altered the course of breast cancer therapy throughout the nation and the world.
- Our decisive finding demonstrating the ability of activated T-cell infusions to re-establish immune function after transplant for Multiple Myeloma has the potential to lead to tumor specific vaccine therapies for many different diseases.
- Our Program is an approved transplant facility by the National Marrow Donor Program.
- Penn clinician pioneered the revolution regarding the availability of alternate donors both from mismatched sibling and unrelated volunteers.
- Our investigators showed the value of blood derived stem cell transplant and the use of less toxic non-myeloablative preparatory regimens, which have greatly improved the outcome and decreased the toxicity of allogeneic transplant.
- Our prestigious trials comparing the non-myeloablative approach to autologous transplant in Multiple Myeloma and Non-Hodgkin’s Lymphoma led the Leukemia and Lymphoma Society to fund a prestigious five year multi-million dollar Specialized Center of Research Award to investigators within the Program to further these innovative trials.
- Our clinicians and investigators are active throughout the region in providing educational events for patients and health care providers.
- Our faculty also serve as medical advisors for area outreach organizations, such as the Multiple Myeloma Networking Group and the Leukemia and Lymphoma Society. Our clinicians have received numerous awards for their outstanding patient support activities.